FDA Inspection 1219108 — Celltrion Pharm, Inc.

Celltrion Pharm, Inc. — FEI 3012279978

The FDA completed an inspection of Celltrion Pharm, Inc. on Sep 14, 2023 in Cheongju. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 3 citations were issued during this inspection. Product area: Devices.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 14, 2023
Fiscal Year
2023
Product Type
Devices
Project Area
Compliance: Devices
Location
Cheongju (Korea (the Republic of))

Citations

IDCFRDescription
312521 CFR 820.80(d)Lack of or inadequate final acceptance procedures
313021 CFR 820.100(a)Lack of or inadequate procedures
366621 CFR 820.20(c)Management review - Lack of or inadequate procedures

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.